Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

In vitroeffect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells

(2014) Alaaeldin Shablak et al.   EXPERT OPINION ON PHARMACOTHERAPY

Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation

(2013) Iori Sakai et al.   BJU INTERNATIONAL

Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer

(2013) R Rosa et al.   BRITISH JOURNAL OF CANCER

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

(2013) Maria Serova et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells

(2012) Chieh-Lin Jerry Teng et al.   ANNALS OF HEMATOLOGY

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model

(2012) Y Kususda et al.   BRITISH JOURNAL OF CANCER

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells

(2012) I Tsaur et al.   BRITISH JOURNAL OF CANCER

Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells

(2012) Eva Juengel et al.   CANCER LETTERS

PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A

(2012) Nikolaos Patsoukis et al.   CELL CYCLE

Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma

(2012) Chi-Chang Chen et al.   Clinical Genitourinary Cancer

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

(2012) Kwonoh Park et al.   MEDICAL ONCOLOGY

High cytoplasmic expression of p27Kip1 is associated with a worse cancer-specific survival in clear cell renal cell carcinoma

(2011) Stephan Kruck et al.   BJU INTERNATIONAL

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

(2011) Camillo Porta et al.   BJU INTERNATIONAL

The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line

(2011) Igor Tsaur et al.   CANCER LETTERS

Autocrine CSF-1 and CSF-1 Receptor Coexpression Promotes Renal Cell Carcinoma Growth

(2011) J. Menke et al.   CANCER RESEARCH

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

(2011) Camillo Porta et al.   EUROPEAN JOURNAL OF CANCER

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

(2011) Giuseppe Di Lorenzo et al.   EXPERT OPINION ON PHARMACOTHERAPY

ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway

(2011) Ping Lin et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence

(2011) T. E. Hutson   ONCOLOGIST

NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation

(2010) T Hosono et al.   BRITISH JOURNAL OF CANCER

EAU Guidelines on Renal Cell Carcinoma: The 2010 Update

(2010) Börje Ljungberg et al.   EUROPEAN UROLOGY

Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms

(2009) Peter Mulders   BJU INTERNATIONAL

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

(2009) Eva Juengel et al.   BMC CANCER

Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma

(2009) Tao Zhang et al.   CANCER LETTERS

Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma

(2009) M.P. Sablin et al.   JOURNAL OF UROLOGY

Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth

(2009) James J. Gibbons et al.   SEMINARS IN ONCOLOGY